Your browser doesn't support javascript.
loading
Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study.
Hochhaus, A; Rosti, G; Cross, N C P; Steegmann, J L; le Coutre, P; Ossenkoppele, G; Petrov, L; Masszi, T; Hellmann, A; Griskevicius, L; Wiktor-Jedrzejczak, W; Rea, D; Coriu, D; Brümmendorf, T H; Porkka, K; Saglio, G; Gastl, G; Müller, M C; Schuld, P; Di Matteo, P; Pellegrino, A; Dezzani, L; Mahon, F-X; Baccarani, M; Giles, F J.
Afiliación
  • Hochhaus A; Abteilung Hämatologie/Onkologie, Klinik für Innere Medizin II, Universitätsklinikum Jena, Jena, Germany.
  • Rosti G; Department of Hematology and Oncology, University of Bologna, Bologna, Italy.
  • Cross NC; Faculty of Medicine, University of Southampton, Southampton, UK.
  • Steegmann JL; Hospital Universitario de la Princesa, IIS-IP, Madrid, Spain.
  • le Coutre P; Charité-Universitätsmedizin Berlin, Berlin, Germany.
  • Ossenkoppele G; VU University Medical Center, Amsterdam, The Netherlands.
  • Petrov L; Ion Chiricuta Institute of Oncology, Cluj, Romania.
  • Masszi T; Department of Haematology and Stem Cell Transplantation, St István and St László Hospital, Budapest, Hungary.
  • Hellmann A; Medical University of Gdansk, Gdansk, Poland.
  • Griskevicius L; Vilnius University Hospital Santariskiu Klinikos, Vilnius University, Vilnius, Lithuania.
  • Wiktor-Jedrzejczak W; Department of Hematology, Medical University of Warsaw, Warsaw, Poland.
  • Rea D; Service d'Hématologie Adulte et INSERM UMR1160, Hôpital Saint-Louis, Paris, France.
  • Coriu D; Fundeni Clinical Institute, Bucharest, Romania.
  • Brümmendorf TH; Universitätsklinikum RWTH Aachen, Aachen, Germany.
  • Porkka K; Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.
  • Saglio G; Division of Internal Medicine & Hematology, University of Turin, Orbassano, Italy.
  • Gastl G; Innere Medizin, Medizinische Universität Innsbruck, Innsbruck, Austria.
  • Müller MC; Universitätsmedizin Mannheim, University of Heidelberg, Mannheim, Germany.
  • Schuld P; Novartis Pharma AG, Basel, Switzerland.
  • Di Matteo P; Novartis Oncology Region Europe, Origgio, Italy.
  • Pellegrino A; Novartis Oncology Region Europe, Origgio, Italy.
  • Dezzani L; Novartis Oncology Region Europe, Origgio, Italy.
  • Mahon FX; Laboratoire Hématopoïèse Leucémique et Cible Thérapeutique, Université Victor Ségalen, Bordeaux, France.
  • Baccarani M; Department of Hematology and Oncology, University of Bologna, Bologna, Italy.
  • Giles FJ; Northwestern Medicine Developmental Therapeutics Institute, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA.
Leukemia ; 30(1): 57-64, 2016 Jan.
Article en En | MEDLINE | ID: mdl-26437782

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 6_ODS3_enfermedades_notrasmisibles Problema de salud: 6_leukemia Asunto principal: Pirimidinas / Proteínas Tirosina Quinasas / Leucemia Mielógena Crónica BCR-ABL Positiva / Inhibidores de Proteínas Quinasas Tipo de estudio: Clinical_trials / Guideline Límite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Leukemia Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2016 Tipo del documento: Article País de afiliación: Alemania

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 6_ODS3_enfermedades_notrasmisibles Problema de salud: 6_leukemia Asunto principal: Pirimidinas / Proteínas Tirosina Quinasas / Leucemia Mielógena Crónica BCR-ABL Positiva / Inhibidores de Proteínas Quinasas Tipo de estudio: Clinical_trials / Guideline Límite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Leukemia Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2016 Tipo del documento: Article País de afiliación: Alemania
...